DNA Quality Outweighs Bone Source - Scorecard - MDSpire

DNA Quality Outweighs Bone Source

Background DNA burden was more strongly associated with sequencing profile completeness than bone source in unidentified human remains.

  • By

  • Andrea Surnit

  • May 19, 2026

  • 5 min

Share

Clinical Scorecard: DNA Quality Outweighs Bone Source

At a Glance

CategoryDetail
ConditionForensic genome sequencing of skeletal remains
Key MechanismsMassively parallel sequencing and SNP profiling
Target PopulationUnidentified human remains
Care SettingForensic laboratories

Key Highlights

  • 399 out of 500 samples met the DNA threshold for sequencing.
  • Call rates ranged from 8% to 91%, with 95.7% achieving rates above 50%.
  • Petrous bone samples had the lowest failure-to-progress rate at 6.5%.
  • Standard quantitative DNA metrics guide workflow but cannot predict high-completeness profiles.
  • 93.2% of sequenced samples achieved call rates of at least 60%.

Guideline-Based Recommendations

Diagnosis

  • Use quantitative PCR to assess human DNA quantity in skeletal samples.

Management

  • Prioritize petrous bone samples for sequencing due to lower failure rates.

Monitoring & Follow-up

  • Evaluate call rates to determine suitability for genealogical databases.

Risks

  • Current metrics may not capture all factors affecting sequencing success.

Patient & Prescribing Data

Individuals represented by unidentified skeletal remains.

Profiles with low call rates may still yield useful genetic information.

Clinical Best Practices

  • Implement machine-learning models to improve prediction of sequencing outcomes.
  • Consider environmental exposure and preservation status when evaluating samples.
  • Use a combination of DNA metrics for a comprehensive assessment of sample viability.

Related Resources & Content

Original Source(s)

DNA Quality Outweighs Bone Source

  • by Andrea Surnit

  • May 19, 2026

Related Content

Combined Clavicle Model May Improve Age Estimates

Combined approach shows higher sensitivity than traditional thresholds for classifying legal adulthood.

Cutaneous Rhabdomyosarcoma May Mask Melanoma

Molecular and epigenetic profiling suggested most tumors in a rare cutaneous sarcoma cohort were better classified as transdifferentiated melanoma.

FDA Approves New First-Line TNBC Regimen

Phase 3 results showed longer progression-free survival with pembrolizumab plus sacituzumab govitecan-hziy than with pembrolizumab plus chemotherapy in previously untreated PD-L1-positive advanced triple-negative breast cancer.